VENTURE CAPITAL POST

Isomorphic Labs, a subsidiary of Alphabet Inc., is set to accelerate AI-driven drug discovery after it entered into strategic research collaboration agreements with Novartis AG and Eli Lilly & Co.

GlaxoSmithKline could consider more partial public share offerings for component units as it evolves in the coming years, potentially pointing to a break-up of the group if this offers value to shareholders.

GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said.

Swiss pharmaceutical group Novartis said on Tuesday the European Commission had approved an additional treatment for its eyecare unit Alcon's Travatan treatment for glaucoma, a chronic, sight-threatening eye disease.

Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro ($1.4 million) price tag, a new record for a medicine to treat a rare disease.

Swiss drugmaker Novartis AG (NOVN.VX) said three members of its executive committee would leave the company following the completion of transactions with GlaxoSmithKline (GSK.L) and Eli Lilly (LLY.N) to divest three units.

EU antitrust regulators will open an extensive probe into Zimmer's (ZMH.N) $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.

Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.

Sanofi is looking to grasp a good hold in Africa through acquisition of business units, according to the firm's CEO Chris Viehbacher who told Reuters.

Vernalis is pleased to announce the achievement of the first milestone in its research collaboration with Asahi Kasei Pharma (AKP).

Switzerland-based drug manufacturer Novartis will be buying closely-held Massachusetts-based biotechnology firm so it will grow its range of immunotherapeutics products to treat cancer, Bloomberg reported.

Drugmakers from Europe are getting lured to the Boston-Cambridge area as the biotechnology boom makes it the envy of other biotechnolgy hubs in the world, Bloomberg reported.